Bristol Myers Squibb manufactures Yervoy [1].
What is Yervoy used for?
Yervoy (ipilimumab) is a medication used in the treatment of certain types of cancer. It is prescribed for unresectable or metastatic melanoma [2]. It is also used for the treatment of pediatric patients aged 12 years and older with certain types of melanoma [2]. In combination with other treatments, Yervoy is used for advanced renal cell carcinoma and unresectable or metastatic melanoma [2].
How does Yervoy work?
Yervoy is an immunotherapy that works by blocking the CTLA-4 protein. CTLA-4 is a protein receptor found on T-cells. By blocking CTLA-4, Yervoy helps to unleash the immune system's T-cells, allowing them to attack cancer cells [2].
When does Yervoy's patent protection end?
Information regarding the specific patent expiry dates for Yervoy is not publicly available through the provided sources. However, patent landscapes for pharmaceuticals can be complex, involving multiple patents for the drug substance, formulation, and methods of use. Websites like DrugPatentWatch.com track such information [3].
Can other companies produce Yervoy?
Following the expiry of patents and exclusivity periods, other companies may be able to produce generic versions of Yervoy, provided they receive regulatory approval. For Yervoy, which is a biologic drug, the pathway would be through biosimilars rather than traditional generics.
What are the side effects of Yervoy?
Yervoy can cause immune system reactions, where the immune system attacks healthy organs and tissues. These reactions can be severe and may affect any part of the body. Symptoms can include lung problems, liver problems, nerve problems, hormone gland problems, skin problems, and kidney problems [2]. Other common side effects include fatigue, diarrhea, rash, and itching [2].
What is the clinical efficacy of Yervoy?
In clinical trials for advanced melanoma, Yervoy demonstrated an improvement in overall survival compared to vaccines [2]. For advanced renal cell carcinoma, when used in combination with nivolumab, it showed improved overall survival compared to sunitinib [2].
Where can I find more information about Yervoy?
More detailed information about Yervoy, including its uses, dosage, and potential side effects, can be found on the prescribing information available from the manufacturer. Resources like DrugPatentWatch.com can also offer insights into the drug's patent and market status [3].
Who are the main competitors to Yervoy?
The competitive landscape for Yervoy includes other immunotherapy agents and combination therapies used for melanoma and renal cell carcinoma. Competitors can vary depending on the specific indication and the treatment regimen.
What is the regulatory status of Yervoy?
Yervoy is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) for specific oncological indications. Its approval is based on clinical trial data demonstrating its safety and efficacy [2].
What is the typical dosage and administration of Yervoy?
Yervoy is administered intravenously (IV) as an infusion. The dosage and frequency depend on the specific cancer being treated and whether it is used alone or in combination with other therapies [2].
---
1. Bristol Myers Squibb. (n.d.). Bristol Myers Squibb - Our Company.
2. Yervoy Prescribing Information. (n.d.). Bristol Myers Squibb.
3. DrugPatentWatch.com. (n.d.).